About all

Comparing Edluar vs Ambien: Sublingual and Oral Zolpidem Efficacy for Insomnia Treatment

by alexxlab

How does sublingual zolpidem (Edluar) compare to oral zolpidem (Ambien) for treating insomnia. What are the key differences in onset of action and sleep induction between these two formulations. How do the efficacy and safety profiles of sublingual and oral zolpidem compare in clinical studies.

Understanding Zolpidem: Sublingual vs Oral Formulations

Zolpidem is a widely prescribed medication for the treatment of insomnia. It comes in two main formulations: sublingual (Edluar) and oral (Ambien). While both contain the same active ingredient, their routes of administration and onset of action differ significantly.

Sublingual zolpidem, marketed as Edluar, is designed to be placed under the tongue where it dissolves rapidly and is absorbed directly into the bloodstream. Oral zolpidem, known as Ambien, is swallowed as a tablet and must pass through the digestive system before taking effect.

Key Differences Between Sublingual and Oral Zolpidem

  • Route of administration: Sublingual vs oral
  • Onset of action: Faster for sublingual formulation
  • Absorption: Direct into bloodstream vs through digestive system
  • Dosage: Lower effective dose for sublingual formulation

Comparative Efficacy: Edluar vs Ambien in Clinical Studies

A randomized, double-blind, cross-over study conducted by Staner et al. compared the hypnotic effects of sublingual zolpidem (Edluar) 10 mg to oral zolpidem (Ambien) 10 mg in patients with primary insomnia. The study utilized polysomnography (PSG) to objectively measure sleep parameters.

Primary Outcome Measures

  • Latency to persistent sleep (LPS)
  • Sleep onset latency (SOL)
  • Latency to stage 1 sleep (ST1L)

The results of this study demonstrated significant advantages for sublingual zolpidem in terms of sleep induction:

How much faster did sublingual zolpidem induce sleep compared to oral zolpidem? Sublingual zolpidem shortened LPS by 34% or 10.3 minutes compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001).

Were there improvements in other sleep onset parameters? Yes, both SOL and ST1L were also significantly shortened with sublingual zolpidem (p < 0.01).

Sleep Maintenance and Overall Efficacy

While the primary focus of the study was on sleep induction, it’s important to consider the overall efficacy of both formulations throughout the night.

How did sublingual and oral zolpidem compare in terms of sleep maintenance? The study found that both formulations were comparable in terms of sleep maintenance properties, as measured by total sleep time (TST).

This suggests that while sublingual zolpidem may have advantages in initiating sleep, both formulations are effective in maintaining sleep throughout the night.

Subjective Sleep Quality and Residual Effects

Did patients report differences in subjective sleep quality between the two formulations? The study found no significant differences in subjective sleep improvement between sublingual and oral zolpidem.

Were there any differences in next-day residual effects? No significant differences were observed in next-day residual effects between the two treatments.

Safety and Tolerability of Sublingual vs Oral Zolpidem

Safety is a crucial consideration when comparing medication formulations. The study by Staner et al. provided insights into the tolerability of both sublingual and oral zolpidem.

How well were the two formulations tolerated by patients? Both routes of administration were reported to be well tolerated, with no significant differences in adverse events between sublingual and oral zolpidem.

This suggests that the improved sleep induction seen with sublingual zolpidem does not come at the cost of increased side effects or safety concerns.

Advantages of Sublingual Zolpidem for Specific Patient Populations

The faster onset of action observed with sublingual zolpidem may be particularly beneficial for certain groups of insomnia patients.

Potential Benefits for:

  • Patients with difficulty initiating sleep
  • Those experiencing transient insomnia
  • Shift workers with irregular sleep schedules
  • Individuals who wake up in the middle of the night and have difficulty returning to sleep

Are there any specific patient populations that might benefit most from sublingual zolpidem? Patients with sleep onset insomnia or those who require a rapid sleep-inducing effect may find sublingual zolpidem particularly effective.

Dosing Considerations: Sublingual vs Oral Zolpidem

An important factor to consider when comparing sublingual and oral zolpidem is the potential for dose reduction with the sublingual formulation.

Can lower doses of sublingual zolpidem be as effective as standard oral doses? A study by Valente et al. found that lower doses of sublingual zolpidem were more effective than oral zolpidem in anticipating sleep onset in healthy volunteers.

This suggests that patients may be able to achieve the desired hypnotic effect with a lower overall dose of zolpidem when using the sublingual formulation, potentially reducing the risk of side effects or dependence.

Implications for Prescribing

  • Potential for lower effective doses with sublingual formulation
  • Reduced risk of side effects and dependence
  • Improved flexibility in dosing for individual patient needs

Long-term Efficacy and Safety Considerations

While short-term studies have demonstrated the efficacy of both sublingual and oral zolpidem, it’s important to consider the long-term use of these medications for chronic insomnia.

Are there any differences in long-term efficacy or safety between sublingual and oral zolpidem? Long-term comparative studies are limited, but both formulations are generally considered effective and safe for short-term use in treating insomnia.

However, as with all sleep medications, there are concerns about tolerance, dependence, and the potential for rebound insomnia with prolonged use. These factors should be carefully considered and discussed between healthcare providers and patients when determining the most appropriate treatment approach for chronic insomnia.

Recommendations for Long-term Management

  • Regular assessment of ongoing need for medication
  • Consideration of non-pharmacological interventions (e.g., cognitive behavioral therapy for insomnia)
  • Periodic attempts at dose reduction or discontinuation
  • Monitoring for signs of tolerance or dependence

Patient Preference and Adherence

The choice between sublingual and oral zolpidem may also be influenced by patient preference and adherence factors.

What factors might influence a patient’s preference for sublingual or oral zolpidem? Patients may prefer sublingual zolpidem for its faster onset of action, ease of administration without water, and potential for lower dosing. Conversely, some patients may prefer the familiarity of oral tablets or find the taste of sublingual formulations unpleasant.

Factors Affecting Patient Adherence

  • Ease of administration
  • Perceived efficacy in inducing sleep
  • Presence or absence of side effects
  • Cost and insurance coverage
  • Personal preferences for medication formulations

Healthcare providers should discuss these factors with patients to determine the most appropriate formulation based on individual needs and preferences.

Future Directions in Zolpidem Research and Development

As our understanding of sleep disorders and pharmacological interventions continues to evolve, ongoing research into zolpidem formulations and delivery methods may lead to further innovations in insomnia treatment.

What potential future developments can we expect in zolpidem formulations? Research may focus on optimizing delivery methods to further improve onset of action, reduce side effects, or provide more targeted therapy for specific types of insomnia.

Areas of Potential Future Research

  • Novel delivery systems (e.g., transdermal patches, nasal sprays)
  • Combination therapies with other sleep-promoting agents
  • Personalized medicine approaches based on genetic or physiological factors
  • Long-term safety and efficacy studies comparing different formulations
  • Investigation of zolpidem’s potential in treating other sleep disorders

As research progresses, it’s likely that we’ll see continued refinement and improvement in zolpidem formulations, potentially offering even more effective and tailored treatment options for individuals suffering from insomnia.

In conclusion, the comparison between sublingual zolpidem (Edluar) and oral zolpidem (Ambien) reveals important differences in onset of action and sleep induction, with sublingual formulations showing advantages in these areas. However, both formulations demonstrate comparable efficacy in sleep maintenance and overall subjective sleep quality. The choice between sublingual and oral zolpidem should be made based on individual patient needs, preferences, and clinical factors, with ongoing monitoring and reassessment to ensure optimal treatment outcomes for those suffering from insomnia.

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia

Randomized Controlled Trial

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Corinne Staner 
1
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliations

Affiliation

  • 1 Forenap Pharma, Rouffach, France.

  • PMID:

    20397964

  • DOI:

    10.1185/03007991003788225

Randomized Controlled Trial

Corinne Staner et al.

Curr Med Res Opin.

2010 Jun.

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Authors

Corinne Staner 
1
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliation

  • 1 Forenap Pharma, Rouffach, France.

  • PMID:

    20397964

  • DOI:

    10.1185/03007991003788225

Abstract


Objective:

To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).


Research and methods:

This was a randomized, double-blind, two-period, cross-over multi-centre study in which each period comprised two successive PSG recording nights. Treatment was administered when PSG recordings started. Subjective sleep and residual effects were assessed the next morning.


Results:

Seventy female and male patients aged 19-64 were analysed. Sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes as compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001). SOL and ST1L were also significantly shortened (p < 0.01). Furthermore the two formulations were comparable in terms of sleep maintenance properties based on total sleep time (TST). The improvement in subjective sleep and next-day residual effects did not differ between the two treatments. Both routes of administration were well tolerated.


Conclusions:

The results demonstrate that sublingual zolpidem is superior to an equivalent dose of oral zolpidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.

Similar articles

  • Sublingual zolpidem (Edluar™; Sublinox™).

    Yang LP, Deeks ED.

    Yang LP, et al.
    CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
    CNS Drugs. 2012.

    PMID: 23034583

    Review.

  • Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

    Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.

    Staner L, et al.
    Sleep Med. 2009 Jun;10(6):616-20. doi: 10.1016/j.sleep.2008.06.008. Epub 2008 Nov 8.
    Sleep Med. 2009.

    PMID: 18996742

    Clinical Trial.

  • Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

    Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

    Roth T, et al.
    Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3.
    Sleep Med. 2006.

    PMID: 16815744

    Clinical Trial.

  • Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers.

    Valente KD, Hasan R, Tavares SM, Gattaz WF.

    Valente KD, et al.
    Sleep Med. 2013 Jan;14(1):20-3. doi: 10.1016/j.sleep.2012.09.003. Epub 2012 Dec 4.
    Sleep Med. 2013.

    PMID: 23218533

    Clinical Trial.

  • A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

    Staner L, Danjou P, Luthringer R.

    Staner L, et al.
    Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
    Expert Rev Neurother. 2012.

    PMID: 22288669

    Review.

See all similar articles

Cited by

  • Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.

    Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D.

    Castro LS, et al.
    Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20.
    Braz J Psychiatry. 2020.

    PMID: 31859791
    Free PMC article.

    Clinical Trial.

  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL.

    Sateia MJ, et al.
    J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470.
    J Clin Sleep Med. 2017.

    PMID: 27998379
    Free PMC article.

  • Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem.

    Xia B, Yang Z, Zhou H, Lukacova V, Zhu W, Milewski M, Kesisoglou F.

    Xia B, et al.
    AAPS J. 2015 May;17(3):631-42. doi: 10.1208/s12248-015-9727-7. Epub 2015 Feb 26.
    AAPS J. 2015.

    PMID: 25716146
    Free PMC article.

  • Sublingual zolpidem (Edluar™; Sublinox™).

    Yang LP, Deeks ED.

    Yang LP, et al.
    CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
    CNS Drugs. 2012.

    PMID: 23034583

    Review.

Publication types

MeSH terms

Substances

Sublingual zolpidem (Edluar™; Sublinox™) – PubMed

Review

. 2012 Nov;26(11):1003-10.

doi: 10.1007/s40263-012-0009-y.

Lily P H Yang 
1
, Emma D Deeks

Affiliations

Affiliation

  • PMID:

    23034583

  • DOI:

    10.1007/s40263-012-0009-y

Review

Lily P H Yang et al.

CNS Drugs.

2012 Nov.

. 2012 Nov;26(11):1003-10.

doi: 10.1007/s40263-012-0009-y.

Authors

Lily P H Yang 
1
, Emma D Deeks

Affiliation

  • PMID:

    23034583

  • DOI:

    10. 1007/s40263-012-0009-y

Abstract

Zolpidem is a non-benzodiazepine hypnotic used in the short-term treatment of insomnia. A sublingual orally disintegrating tablet formulation of zolpidem (Edluar™; Sublinox™) has been developed to provide a more rapid onset of action than oral immediate-release zolpidem. Sublingual zolpidem has demonstrated bioequivalence to oral zolpidem. In a randomized, double-blind, double-dummy, crossover, multi-centre study in adult patients with primary insomnia (n = 70), a single 10-mg dose of sublingual zolpidem significantly reduced latency to persistent sleep (primary endpoint) compared with a single 10-mg dose of oral immediate-release zolpidem. Sleep-onset latency and latency to stage 1 sleep were also significantly shorter with sublingual zolpidem than with oral zolpidem. Moreover, compared with the oral formulation, sublingual zolpidem was noninferior in terms of total sleep time and did not significantly differ in terms of duration of wake after sleep onset. Sublingual zolpidem was generally well tolerated in this trial, with most adverse events being of mild or moderate severity. The overall tolerability profile of sublingual zolpidem was similar to that of oral zolpidem.

Similar articles

  • A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

    Staner L, Danjou P, Luthringer R.

    Staner L, et al.
    Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
    Expert Rev Neurother. 2012.

    PMID: 22288669

    Review.

  • Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.

    Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M.

    Roth T, et al.
    Sleep. 2013 Feb 1;36(2):189-96. doi: 10.5665/sleep.2370.
    Sleep. 2013.

    PMID: 23372266
    Free PMC article.

    Clinical Trial.

  • Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.

    Staner C, Joly F, Jacquot N, Vlasova ID, Nehlin M, Lundqvist T, Edenius C, Staner L.

    Staner C, et al.
    Curr Med Res Opin. 2010 Jun;26(6):1423-31. doi: 10.1185/03007991003788225.
    Curr Med Res Opin. 2010.

    PMID: 20397964

    Clinical Trial.

  • Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

    Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB; Intermezzo Study Group.

    Roth T, et al.
    Sleep. 2008 Sep;31(9):1277-84.
    Sleep. 2008.

    PMID: 18788653
    Free PMC article.

    Clinical Trial.

  • Zolpidem’s use for insomnia.

    Monti JM, Spence DW, Buttoo K, Pandi-Perumal SR.

    Monti JM, et al.
    Asian J Psychiatr. 2017 Feb;25:79-90. doi: 10.1016/j.ajp.2016.10.006. Epub 2016 Oct 12.
    Asian J Psychiatr. 2017.

    PMID: 28262178

    Review.

See all similar articles

References

    1. Int J Clin Pharmacol Ther. 1996 Apr;34(4):178-83

      –

      PubMed

    1. J Clin Psychiatry.